曲妥珠单抗联合伊沙匹隆对晚期转移性乳腺癌患者的疗效及CEA、CA125、CA15-3水平的影响

Efficacy of Trastuzumab Combined with Ixabepilone in Patients with Advanced Metastatic Breast Cancer and Influence of the levels of CEA,CA125 and CA15-3

目的:研究曲妥珠单抗联合伊沙匹隆对晚期转移性乳腺癌(MBC)患者的疗效以及癌胚抗原(CEA)、糖类抗原125(CA125)和糖类抗原15-3(CA15-3)水平的影响。方法:选取2016年7月-2017年6月于本院治疗的晚期MBC患者124例作为研究对象,按照随机数字表法将其分为观察组和对照组,各62例。观察组给予曲妥珠单抗联合伊沙匹隆治疗,对照组单独使用曲妥珠单抗。比较两组的临床疗效和CEA、CA125、CA15-3水平,以及不良反应发生情况。结果:观察组的总有效率为74.19%,明显高于对照组的45.16%,差异有统计学意义(χ~2=5.073,P=0.024)。治疗后,两组的CEA、CA125和CA15-3水平均明显低于治疗前,且观察组均明显低于对照组,差异均有统计学意义(P<0.05)。观察组的各项不良反应的发生情况与对照组比较,差异均无统计学意义(P>0.05)。结论:曲妥珠单抗与伊沙匹隆联合使用治疗晚期MBC的效果较好,且安全性较高,并可降低CEA、CA125和CA15-3水平,值得在临床上推广。

Objective：To study the efficacy of Trastuzumab combined with Ixabepilone in patients with advanced metastasis breast cancer（MBC） and influence of the levels of carcinoembryonic antigen（CEA）, carbohydrate antigen 125（CA125） and carbohydrate antigen 15-3（CA15-3）.Method：A total of 124 patients with advanced MBC who were treated in our hospital from July 2016 to June 2017 were selected as study subjects.According to the random number table method,they were divided into observation group and control group, 62 cases in each group.The observation group was treated with Trastuzumab combined with Ixabepilone. The control group was treated with Trastuzumab alone.The clinical efficacy,the level of CEA,CA125 and CA15-3 and the adverse reactions between the two groups were compared.Result：The total effective rate of the observation group was 74.19%,which was significantly higher than 45.16% of the control group,the difference was statistically significant（ χ^2=5.073,P=0.024）.After treatment,the levels of CEA,CA125 and CA15-3 in the two groups were significantly lower than those before treatment,and the observation group were significantly lower than those in the control group,the differences were statistically significant（P〈0.05）.There were no significant differences in the incidence of adverse reactions between the observation group and the control group（P〈0.05）. Conclusion：The combined use of Trastuzumab and Ixabepilone in the treatment of advanced MBC is effective and safe,and can reduce the levels of CEA,CA125 and CA15-3,which is worth of popularizing in clinic.